Skip to content

Microdosing: all studies

Page 55 of 56: studies 541 to 550 of 555, newest first. Back to the microdosing overview

Research

Psychedelics and potential benefits in “healthy normals”: A review of the literature

Journal of Psychedelic Studies September 1, 2019 Sam Gandy 44 citations

We are in the midst of a psychedelic research renaissance. With research examining the efficacy of psychedelics as a treatment for a range of mental health indications still in its early stages, there is an increasing body of research to show that careful use of psychedelics can yield a variety of benefits in “healthy normals” and so lead to “the betterment of well people.” Psychedelics have...

Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers

Biological Psychiatry June 3, 2019 Anya K. Bershad, Scott T. Schepers, Michael P. Bremmer et al. 176 citations

BackgroundNumerous anecdotal reports suggest that repeated use of very low doses of lysergic acid diethylamide (LSD), known as microdosing, improves mood and cognitive function. These effects are consistent both with the known actions of LSD on serotonin receptors and with limited evidence that higher doses of LSD (100-200 μg) positively bias emotion processing. Yet, the effects of such...

Chronic, Intermittent Microdoses of the Psychedelic N , N -Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents

ACS Chemical Neuroscience March 4, 2019 Lindsay P. Cameron, Charlie J. Benson, Brian C. Defelice et al. 163 citations

-dimethyltryptamine (DMT). The behavioral and cellular effects of this dosing regimen were distinct from those induced following a single high dose of the drug. We found that chronic, intermittent, low doses of DMT produced an antidepressant-like phenotype and enhanced fear extinction learning without impacting working memory or social interaction. Additionally, male rats treated with DMT on...

DOI: 10.1021/acschemneuro.8b00692 (opens in new tab) Anxiety Mood Pharmacology Clinical psychology

Psychedelic medicine: The biology underlying the persisting psychedelic effects

Medical Hypotheses February 11, 2019 K.p.c. Kuypers 34 citations

Psychedelic substances have regained interest as therapeutic agents in the treatment of stress-related disorders. The effects seem to be of persisting nature even after a single dose. Also in lower than 'regular' recreational doses, so-called micro-doses, without the typical effects on consciousness, users report beneficial effects on cognitive processes and well-being. The exact...

Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.

Experimental and Clinical Psychopharmacology January 10, 2019 Farhana Sakloth, Elizabeth Leggett, Megan J. Moerke et al. 42 citations

The prototype 5-HT2A receptor agonist hallucinogens LSD, mescaline, and psilocybin are classified as Schedule 1 drugs of abuse by the U.S. Drug Enforcement Administration. Accumulating clinical evidence has also suggested that acute or repeated "microdosing" with these drugs may have utility for treatment of some mental health disorders, including drug abuse and depression. The goal of the...

(Micro-) “Psychedelic” Experiences: from the 1960s creativity at the workplace to the 21st Century neuro-newspeak

Ethnologie Française 2019 M. Aronov

espanolDesde los anos 1990, la reevaluacion de los alucinogenos, o psicodelicos, como categoria de sustancias ha suscitado hipotesis de investigacion sugiriendo la utilidad de “micro dosis” de psicodelicos para mejorar las actividades de la vida cotidiana. Aun que en estudios en management estas sustancias han sido percibidas por unos como una herramienta para el estudio de la “creatividad”, el...

Advances in Psychedelic Medicine

2019 17 citations

Researchers, program administrators, and practicing clinicians explain the most recent developments in using psychedelic substances to treat psychological, physiological, and social problems. More than a decade ago, the U.S. government lifted its ban on all testing of psychedelic substances. Winkelman and Sessa now provide updated scientific research and applications of these substances, now...

The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial

Psychopharmacology November 26, 2018 Steliana Yanakieva, Naya Polychroni, Neiloufar Family et al. 169 citations

RATIONALE: Previous research demonstrating that lysergic acid diethylamide (LSD) produces alterations in time perception has implications for its impact on conscious states and a range of psychological functions that necessitate precise interval timing. However, interpretation of this research is hindered by methodological limitations and an inability to dissociate direct neurochemical effects...

Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia.

Psychopharmacology February 2018 Elena Martín-González, Ángeles Prados-Pardo, Santiago Mora et al.

Clinical studies have shown that some psychoactive recreational drugs have therapeutic applications in anxiety, depression, and schizophrenia. However, to date, there are few studies on the therapeutic potential efficacy of recreational drugs in compulsive neuropsychiatric disorders. We explored the therapeutic potential of different psychoactive and psychedelic drugs in a preclinical model of...

DOI: 10.1007/s00213-017-4819-y (opens in new tab) Full text (opens in new tab) Compulsivity Psychedelic drugs Psychoactive drugs Schedule-induced polydipsia

Powerful substances in tiny amounts

Nordic Studies on Alcohol and Drugs February 1, 2018 Petter Grahl Johnstad 156 citations

AIMS: This article presents a qualitative interview study of people who microdose with psychedelic drugs, which means that the user takes about one tenth of an ordinary recreational dose. DESIGN: = 21) were recruited at several Internet fora for individual interviews via private messaging. Every participant was male, and the median respondent was in his 30s with a stable job and relationship...

DOI: 10.1177/1455072517753339 (opens in new tab) Anxiety Respondent Mood Clinical psychology +2